{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-115406","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.422882+00:00","generated_at":"2026-06-22T05:07:04.078237+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ocular Therapeutix Q3 DEXTENZA revenue flat at $11.9M; net loss $24.2M; revises 2022 guidance to $48-52M","bullets":["DEXTENZA net product revenue $11.9M in Q3 2022, flat YoY and down ~2% sequentially; 2022 guidance revised to $48-52M (10-20% growth).","Net loss $24.2M ($0.31/share) vs net income $2.7M ($0.03/share) in Q3 2021; includes $1.1M non-cash derivative liability adjustment.","OTX-TKI Phase 1 wet AMD interim: 80% rescue-free at 6 months, 73% at 7 months; Phase 2/3 planned for Q3 2023.","Phase 1 trial for diabetic retinopathy expected to start Q1 2023; OTX-TIC Phase 2 enrollment ongoing, topline data Q4 2023.","Cash and equivalents $121.0M as of Sep 30, 2022; sufficient to fund operations through 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-115406","json":"https://secwatch.observer/filing/0001104659-22-115406.json","markdown":"https://secwatch.observer/filing/0001104659-22-115406.md","text":"https://secwatch.observer/filing/0001104659-22-115406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465922115406/0001104659-22-115406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465922115406/tm2229787d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:07:04.078237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"274be4529f4df463ab4dca93c171e28ef58089fc","claim":"OCULAR THERAPEUTIX, INC updated its the quarter ended September 30, 2022 guidance (reaffirmed).","evidence_excerpt":"On November 7, 2022, Ocular Therapeutix, Inc. announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465922115406/0001104659-22-115406-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}